In vitro Activity of Cefiderocol and Ceftazidime-Avibactam, Against Carbapenemase-Producing Enterobacterales

被引:2
作者
Ozyurt, Ozlem K. [1 ]
Tufanoglu, Pinar [1 ]
Cetinkaya, Ozgul [2 ]
Ozhak, Betil [1 ]
Yazisiz, Hatice [1 ]
Ongut, Gozde [1 ]
Turhan, Ozge [3 ]
Ogunc, Dilara [1 ]
机构
[1] Akdeniz Univ, Fac Med, Dept Med Microbiol, Antalya, Turkey
[2] Univ Hlth Sci, Antalya Training & Res Hosp, Dept Med Microbiol, Antalya, Turkey
[3] Akdeniz Univ, Fac Med, Dept Infect Dis & Clin Microbiol, Antalya, Turkey
关键词
RESISTANCE; COLISTIN;
D O I
10.7754/Clin.Lab.2022.220827
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Carbapenemase production is an issue of significant clinical and public health concern, because of the shortage of effective antimicrobial agents available for treatment. Here, we present antimicrobial susceptibili-ty data of ceftazidime-avibactam, cefiderocol, and other clinically relevant antibiotics for carbapenemase-produc-ing Enterobacterales bloodstream isolates, in accordance with European Committee on Antimicrobial Susceptibili-ty Testing (EUCAST) guidelines. Methods: A total of 133 carbapenemase producing Enterobacterales bloodstream isolates from May 2010 to Sep-tember 2018 were included in the study. Species were identified using matrix-assisted laser-desorption ionization time-of-flight mass spectrometry (Bruker Daltonics, Germany). The presence of the blaKPC, blaNDM, blaOXA-48, blaVIM, and blaIMP carbapenemase genes were investigated by BD Max CRE assay (Becton Dickinson, USA) and in-house PCR. Antimicrobial susceptibility testing was performed by the BD Phoenix automated system (Becton Dickinson, USA), except cefiderocol and colistin. Cefiderocol and colistin susceptibility was determined by disk diffusion and broth microdilution method, respectively. Results: Except for cefiderocol and ceftazidime-avibactam, the percentage of susceptible isolates did not exceed 90% for any of the antibiotics tested. Although none of the isolates were resistant to cefiderocol, the ceftazidime-avibactam resistance rate was 9.8%. All of the ceftazidime-avibactam resistant strains were NDM (New Delhi metallo-beta-lactamases) producers. Among the other clinically relevant antibiotics tested, only amikacin, colistin, tigecycline, and fosfomycin susceptibility rates exceeded 50%. Of the 133 isolates 22.6% were resistant to colistin which is the preferred antibiotic with a second active agent for infections caused by metallo-beta-lactamase pro-ducing Enterobacterales in Turkey. Conclusions: In our study, resistance to ceftazidime-avibactam was detected only in metallo-beta-lactamase pro-ducing Enterobacterales isolates, while cefiderocol was found to be effective against all strains. It is important to monitor regional antimicrobial susceptibility data, as the emergence of antimicrobial resistant phenotypes is di-rectly linked to the use of any given antimicrobial agent.
引用
收藏
页码:155 / 160
页数:6
相关论文
共 25 条
  • [1] Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections
    Ackley, Renee
    Roshdy, Danya
    Meredith, Jacqueline
    Minor, Sarah
    Anderson, William E.
    Capraro, Gerald A.
    Polk, Christopher
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (05)
  • [2] Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate
    Both, Anna
    Buettner, Henning
    Huang, Jiabin
    Perbandt, Markus
    Campos, Cristina Belmar
    Christner, Martin
    Maurer, Florian P.
    Kluge, Stefan
    Koenig, Christina
    Aepfelbacher, Martin
    Wichmann, Dominic
    Rohde, Holger
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (09) : 2483 - 2488
  • [3] Deja E.N., 2021, CLIN MICROBIOL NEWSL, V43, P119, DOI 10.1016/j.clinmicnews.2021.06.004
  • [4] Doi Y, 2020, Bennett's Principles and Practice of Infectious Diseases, P285
  • [5] Food and Drug Administration, 2022, ANT SUSC TEST INT CR
  • [6] Hindler JA, 2020, CLSI SUBCOMMITTEE AN, V5, P1
  • [7] In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates
    Hosbul, Tugrul
    Aydogan, Canset Nur
    Kaya, Sinem
    Bedir, Orhan
    Gumral, Ramazan
    Albay, Ali
    [J]. MIKROBIYOLOJI BULTENI, 2022, 56 (02): : 218 - 229
  • [8] First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate
    Humphries, Romney M.
    Yang, Shangxin
    Hemarajata, Peera
    Ward, Kevin W.
    Hindler, Janet A.
    Miller, Shelley A.
    Gregson, Aric
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (10) : 6605 - 6607
  • [9] ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases
    Jacobs, Michael R.
    Abdelhamed, Ayman M.
    Good, Caryn E.
    Rhoads, Daniel D.
    Hujer, Kristine M.
    Hujer, Andrea M.
    Domitrovic, T. Nicholas
    Rudin, Susan D.
    Richter, Sandra S.
    van Duin, David
    Kreiswirth, Barry N.
    Greco, Chris
    Fouts, Derrick E.
    Bonomo, Robert A.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (01)
  • [10] The difficulties of identifying and treating Enterobacterales with OXA-48-like carbapenemases
    Kidd, J. M.
    Livermore, D. M.
    Nicolau, D. P.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (04) : 401 - 403